Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TARA-002 by Protara Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TARA-002 is under clinical development by Protara Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Risk adjusted net present value: What is the current valuation of Protara Therapeutics's TARA-002?
TARA-002 is a cell therapy commercialized by Protara Therapeutics, with a leading Phase II program in Non Muscle Invasive Bladder...
TARA-002 by Protara Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
TARA-002 is under clinical development by Protara Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC)...
Risk adjusted net present value: What is the current valuation of Protara Therapeutics's TARA-002?
TARA-002 is a cell therapy commercialized by Protara Therapeutics, with a leading Phase II program in Non Muscle Invasive Bladder...